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Abstract   
Tumor relapse after chemotherapy is a major clinical problem, especially for patients with 
inoperable primary and/or metastatic cancer. Tumor-associated macrophages (TAMs) are 
known to both promote key steps in tumor progression and to limit the cytotoxic effects of 
chemotherapeutic agents on mouse tumors. Here, we show that alternatively (M2) activated 
(MRC1+TIE2HiCXCR4Hi) TAMs accumulate around blood vessels in tumors after chemotherapy 
and then promote tumor revascularisation and relapse, in part, via their release of VEGFA.  
Importantly, a similar perivascular, M2-skewed TAM subset was also present in primary human 
breast carcinomas and bone metastases after chemotherapy. While a small proportion of M2 
TAMs were also present in hypoxic tumor areas, when we genetically ablated their ability to 
respond to hypoxia via hypoxia-inducible factors (HIFs) 1 and 2, tumor relapse was unaffected, 
further supporting the role of TAMs in well-oxygenated areas in this phenomenon. TAMs were 
the predominant cells expressing immunoreactive CXCR4 in chemotherapy-treated mouse 
tumors, with the highest levels expressed by MRC1+ TAMs clustering around the tumor 
vasculature.  Furthermore, the primary ligand for CXCR4, CXCL12, was upregulated in these 
perivascular sites after chemotherapy and shown to be selectively chemotactic for MRC1+ 
TAMs. Finally, pharmacological blockade of CXCR4 selectively reduced the numbers of these 
M2-skewed TAMs after chemotherapy, especially those in direct contact with blood vessels, 
resulting in reduced tumor revascularisation and regrowth. These studies highlight a possible 
new strategy to extend the beneficial effects of chemotherapy - the selective targeting of these 
perivascular, relapse-promoting M2-skewed TAMs. 
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Introduction   
The regrowth of tumors after treatment with cytotoxic agents poses a major threat to survival in 
cancer patients, particularly those with inoperable primary and/or metastatic tumors as they 
often rely heavily on chemotherapy to slow tumor growth and reduce its burden. The 
development of resistance results in poor survival rates for patients with, for example, 
inoperable pancreatic or lung cancer, who often survive for less than 12 months after diagnosis 
(1,2).  New therapeutic strategies are, therefore, urgently needed to delay or prevent tumor 
regrowth after early cycles of chemotherapy as these would extend life.   
 Malignant tumors contain various CD11b+ myeloid cells including granulocytes, myeloid-
derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) (3).  The latter 
are recruited as monocytes from the peripheral blood, which are themselves derived from 
progenitor cells in the bone marrow (4,5).  Following entry into tumors, monocytes differentiate 
into macrophages (6) and promote tumor progression by stimulating tumor invasion, 
neovascularisation and metastasis, and suppressing anti-tumor immunity (5,7). TAMs express 
a broad spectrum of activation states between the two extreme forms of ‘classical’ (M1) and 
‘alternative’ (M2) activation, with a tendency towards the latter (8).  M2-skewed TAMs are 
characterized by their upregulation of various receptors including the mannose receptor C-type 
lectin (MRC1/CD206) and the angiopoietin receptor, TIE2 (9). Indeed, TAMs expressing high 
levels of these two receptors have been shown to play an essential role in promoting 
angiogenesis in untreated mouse tumors (10).  
A variety of anti-cancer therapies have been shown to stimulate the recruitment of 
CD11b+ myeloid cells by mouse tumors (11,12).  For example, TAMs accumulate in mouse 
tumors after chemotherapy (13-15), ionizing radiation (16-18) and the vascular disrupting agent, 
combretastatin-A4-P (CA-4-P) (19). Importantly, the mononuclear phagocyte growth factor, 
CSF1 (13), and chemokines, CCL2 (14) and CXCL12 (16,19), are increased in tumors following 
such anti-cancer therapies, and can trigger monocyte recruitment (4,5).  These cells then 
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reduce the efficacy of chemotherapy by limiting vascular permeability via their expression of 
MMP9 (14), promoting resistance to therapy-induced death via their expression of cathepsin 
serine proteases (15) and by suppressing the recruitment/activation of cytotoxic T-cells (12,13). 
Considerable evidence has emerged recently for M2-activated macrophages playing an 
important role in repair and remodelling after tissue injury. For example, they are prominent in 
diseased tissues in spinal cord injury, myocardial infarction and various forms of renal disease, 
(20).  Furthermore, TAMs with similar phenotypes have been implicated in tumor relapse after 
therapies like irradiation and CA-4-P (17,19).  Although MRC1+ TAMs are increased in MMTV-
PyMT mammary tumors after doxorubicin treatment (14), the role of M2 TAMs in tumor relapse 
after chemotherapy has not been defined.  
Our studies show that MRC1+ TAMs are elevated in mouse tumors after treatment with 
various chemotherapeutic agents. Moreover, this TAM subset was further defined as 
MRC1HiTIE2HiCXCR4HiVEGFA+ and shown to accumulate preferentially in vascularised, 
CXCL12-rich regions of tumors after chemotherapy.  Blockade of CXCR4 signalling prevented 
this close association with the tumor vasculature after chemotherapy, resulting in a marked 
delay in subsequent tumor revascularization and relapse.  These findings suggest that selective 
targeting of vessel-associated, M2-skewed TAMs after chemotherapy could increase the 
relapse-free survival of cancer patients. 
 
Materials and Methods 
Mouse studies  
To investigate the mechanisms regulating tumor relapse after chemotherapy, we primarily used 
the Lewis lung carcinoma model (21) and MMTV-PyMT model of breast cancer (15).  These 
syngeneic tumor models respond to chemotherapy with an initial phase of tumor growth 
inhibition, followed by a distinct regrowth phase.  Transgenic tumor models were not considered 
suitable as their responses to some cytotoxic agents can be so minimal that a relapse phase is 
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not evident (13,22). Furthermore, tumors in these models are often multifocal making the 
kinetics of tumor relapse difficult to assess accurately. 
Our mouse studies were conducted in accordance with either UK Home Office 
regulations (CEL/MM/RH), the Veterinary Authorities of the Canton Vaud (MDP), the institutional 
standards of the Research Animals Resource Centre at Memorial Sloan-Kettering Cancer 
Centre (JAJ) and the Albert Einstein College of Medicine Animal Use Committee (JWP).  
LLC1/CTX studies using 8-week old C57BL/6 mice were performed as described previously 
(21). For LLC1/AMD3100 studies; AMD3100 was given concurrently (10 mg/Kg) with CTX, i.p. 
every day for 7 days.  Tumors and organs were harvested at the indicated times.  Mice were 
treated i.p. with pimonidazole (60 mg/Kg) and BrdU (100 mg/Kg) 2h prior to sacrifice to label 
hypoxia and proliferating cells, respectively. 4T1/paclitaxel studies; Female Balb/c mice (>8 
weeks) were orthotopically implanted with 1x106 4T1 murine mammary adenocarcinoma cells.  
Tumors were grown for 10 days before mice were injected i.p. with either cremaphore or 
cremophore+PTX (10 mg/kg) every 5 days for a total of 3 doses, the mice were sacrificed and 
tissues harvested 4 days after the last treatment. Orthotopic MMTV-PyMT/DOX studies were 
performed as previously described (15). Mice bearing implanted tumors were injected i.v. with a 
single dose of DOX (5 mg/kg) when at 250 mm3 and sacrificed 7d post-therapy. 
Monocyte/macrophage-specific ablation of Vegfa studies: Female Tg(Csf1r-Mer-iCre-
Mer)1jwp;Vegfafl/fl)  mice (>8weeks), shown to specifically lack the expression of VEGFA in the 
monocyte/macrophage lineage following treatment with tamoxifen (23), or Cre negative litter 
mates (aged 8 weeks+) were orthotopically implanted with the syngeneic MMTV-PyMT cell line, 
F246-6.  Vegfa floxed mice were the kind gift of Dr Naploeone Ferrar, Genentech.  Mice with 
established tumors were treated with a single i.v. injection of either vehicle (PBS) or DOX (5 
mg/Kg) and 24h later with tamoxifen via their food (3mg/20g body weight/day).  Treatment with 
tamoxifen was then maintained throughout tumor regrowth.  Tumor growth was monitored by 
caliper measurements. In the LLC1/TAM adoptive transfer studies, C57BL/6 mice implanted 
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with LLCs and treated with CTX as outline above, 48h after the last dose of CTX, donor mice 
were sacrificed, their tumors removed, enzymatically dissociated, and MRC1Hi and MRC1Lo 
TAMs were purified by flow cytometry.  Recipient mice were randomised into three groups and 
received either 50 x103 MRC1Hi TAMs, 50 x 103 MRC1Lo TAMs, or saline via a 25 µL intra-
tumoral injection.  Following injection of these cells or saline, tumor re-growth was then 
monitored. 
 
Human breast carcinomas patients and metastatic bone lesions 
Four patients with newly diagnosed breast cancer underwent neoadjuvant chemotherapy as 
previous described (24). Residual tumor tissues were collected at the time of surgery (which 
took place 21-28 days after the last dose of PTX). Biopsies of bone metastatic lesions were also 
obtained from 5 advanced breast cancer patients. All biopsies were obtained under informed 
consent following procedures approved by the Ottawa Health Sciences Research Ethics Board. 
Samples were collected as previously described (25). All biopsies were taken within 6-15 days 
of treatment with either chemotherapy alone (PTX, docetaxel or 5-
fluoruracil/doxorubicin/cyclophosphamide with or without pamidronate. 
 
Immunofluorescence and immunohistochemistry studies 
Frozen tumor sections were blocked with 1% BSA and 5% goat serum for 30 minutes and 
incubated with various primary antibodies (Table 1), for 1h at RT. Alexa Fluor-conjugated anti-
rabbit or anti-rat secondary antibodies were used with unconjugated primary antibodies. For 
BrdU staining, DNA in frozen tissue sections was denatured with 2NHCl for 15 minutes prior to 
immunostaining, as described above. Nuclei in all tumor sections were counterstained with 
DAPI. Formalin-fixed, paraffin-embedded tissues were rehydrated, peroxidase blocked, then 
antigen retrieved, serum blocked and incubated with primary antibodies for 1-2h. Primary 
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antibodies were detected with appropriate ABC or Polymer detection kits followed by 
chromagen staining with DAB. 
 
Distribution of MRC1+ TAMs relative to blood vessels in human primary breast tumors  
The number of MRC1+ TAMs present within a 250µm radius of a given blood vessel was 
counted in 6 randomly selected areas per tumor section.  Then, within this 250 µm radius, the 
distance of each MRC1+ TAM was measured to the nearest vessel and the number of MRC1+ 
TAMs within or beyond 150 µm from that vessel was expressed as a % MRC1+ TAMs within the 
region being analysed. These were defined as ‘perivascular’ or ‘avascular’ MRC1+ TAM subsets 
respectively. 
 
Tumor dissociation/flow cytometry studies  
Tumors were enzymatically dissociated and labelled with antibodies as described previously (9). 
All antibody incubations were performed for 1h at 4oC. Cell staining analyses and cell sorting 
experiments were performed using BD LSRII and BD FACSAria, respectively. 
 
VEGFA ELISA studies 
CD45+CD11b+Ly6G-F4/80+ TAMs were isolated from three pooled, dissociated control and CTX-
treated LLC1 tumors. One hundred thousand sorted cells were seeded in 100 µL of medium 
and cultured overnight.  Conditioned medium was examined for VEFGA release using a mouse 
VEGFA Quantikine Sandwich ELISA (R&D Systems). 
 
Chemotaxis assay 
MRC1+/Hi (CD11b+Ly6G_F4/80+MRC1Hi) and MRC1-/Lo (CD11b+Ly6G_F4/80+MRC1Hi) TAMs were 
FACSorted from dissociated CTX-treated LLC1 tumours and seeded into transwell inserts (4µm 
pores, VWR International), 50x103 cell per well.  Lower chambers contained either medium 
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alone, medium supplemented with 10nM BSA or 10nM recombinant murine CXCL12 (100 
ng/mL). Following an incubation of 6h at 37oC the chambers were dissassembled and the 
membranes stained with crystal violet. The upper surface of each transwell insert was scraped 
to remove non-migrated cells before quantification. 
 
Quantification of spontaneous LLC1 lung metastases 
Sections (4µm thick) were cut from formalin-fixed paraffin-embedded lungs and stained with 
haemotoxylin and eosin. These stained sections were imaged using the Aperio slide scanner 
(Leica Biosystems), and the number of metastases per section and total metastatic area 
quantified using ImageScope analysis software (Leica Biosystems). 
 
Statistics 
All data represent mean values ± SEMs. P values of less than 0.05 were considered to be 
significant. All statistical comparisons were made using the non-parametric Mann-Whitney U-
test (paired or unpaired as appropriate). 
 
 
Results 
M2-skewed (MRC1+TIE2HIVEGFA+) TAMs are abundant in mouse tumors after 
chemotherapy and promote their relapse. 
 Three i.p. injections of the cytotoxic agent, cyclophosphamide (CTX), resulted in the 
complete cessation of LLC1 tumor growth, followed by regrowth beginning 7 days after 
treatment stops (Fig. 1A, left panel). Forty-eight hours after the last CTX injection (day 6), 
LLC1s contained significantly (P<0.05) shorter blood vessels and more hypoxia than size-
matched controls (Fig. S1A).  Consistent with earlier observations for MMTV-PyMT implants 
treated with PTX (13), TAMs were enriched among those leukocytes present in LLC1s 48h post-
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CTX (Fig. S1B). Additionally, there was a significant (P<0.05) increase in the overall number of 
F4/80+ TAMs in CTX-treated LLCs compared to size-matched controls.  This was also seen in 
PTX-treated, orthotopic 4T1 tumors and doxorubicin (DOX)-treated orthotopic MMTV-PyMT 
implants (Fig. S1C).   
 CTX treatment of LLC1s resulted in a significant (P<0.05) increase in the number of 
F4/80+ TAMs expressing the M2-marker, MRC1, relative to size-matched controls.  In contrast, 
there was a significant (P<0.05) drop in F4/80+/MRC1− TAMs after CTX (Fig. 1A, right panels).  
Also, TAMs from CTX-treated LLC1s expressed higher surface MRC1 than those from size-
matched controls (Fig. 1B).  Consistent with previous findings in untreated mouse tumors 
(9,10), MRC1Hi TAMs in CTX-treated LLC1s co-expressed elevated TIE2 (Fig. 1C&D). A similar 
increase in MRC1+ TAMs was also seen in orthotopic 4T1 and MMTV-PyMT implants after PTX 
and DOX, respectively (Fig. S1D). In all 3 models, the vast majority of MRC1+ cells F4/80+ 
TAMs, and the small number of F4/80−MRC1+ (presumably dendritic) cells were not significantly 
increased following treatment with CTX, PTX or DOX (Fig. S2A).  
BrdU uptake was negligible in MRC1+ TAMs in both size-matched control and CTX-
treated LLC1 tumors, indicating their non-proliferative status (Fig. S2B). As chemotherapy-
induced changes in circulating hematopoietic stem and progenitor cells (HS/PCs) could, in 
theory, contribute to the increase of TAM numbers post-therapy, we also performed dual 
immunofluorescence labelling for HS/PC markers, c-Kit and Sca1.  While c-Kit+Sca1+ cells were 
detected in the spleens of LLC1 tumor-bearing mice (positive control for the staining) no such 
cells were detected in either control or CTX-treated LLC1s (Fig. S2C).  These data indicate that 
the chemotherapy-induced increase in TAMs is most likely to be due to increased monocyte 
recruitment rather than the proliferation of existing TAMs or their differentiation from recruited 
HS/PCs.  
We then isolated F4/80+MRC1+/Hi and F4/80+MRC1−/Lo TAMs from CTX-treated LLC1 
tumors by FACS and injected them into CTX-treated LLC1 tumors in littermates (Fig. 2A).  
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MRC1+/Hi TAMs, but not MRC1−/Lo TAMs from treated tumors or TAMs from vehicle-treated 
tumors, accelerated tumor regrowth after CTX. This was accompanied by a significant (P<0.05) 
increase in the number of MRC1+ TAMs, CD31+ blood vessels and a moderate increase in 
BrdU+ (proliferating) cells in CTX-treated LLC1s receiving MRC1+/Hi TAMs. Very few (< 1%) of 
CD45+ leukocytes contained immunodetectable BrdU (Fig. 2B-E). 
MRC1+ TAMs are proangiogenic in untreated tumors and express the important pro-
angiogenic mediator VEGFA (9,26). Moreover, myeloid-specific deletion of VEGFA is known to 
have profound effects on the vascularisation and progression of untreated mouse tumors (27).  
We, therefore, investigated the role of VEGFA derived from MRC1+ TAMs in tumor-relapse after 
chemotherapy. As reported previously in mouse tumors (25), VEGFA was expressed by both 
TAMs and other (F4/80−) cells in control LLC1s (Fig. 3A & Fig. S3A). However, within 48h of 
the last dose of CTX, VEGFA was expressed almost exclusively by MRC1+ TAMs (Fig. S3B). 
As the expression of VEGFA was closely associated with MRC1+ TAMs, and because the latter 
were more abundant in CTX-treated LLCs (Fig. 3B&C), we postulated that the macrophage 
population as a whole found within CTX-treated LLCs might be capable of producing higher 
levels of VEGFA. Indeed, the release of VEGFA was found to be significantly greater for TAMs 
sampled from CTX-treated LLCs (Fig. 3D).   
 MDSCs (CD11b+Gr1+) in tumour-bearing mice are also reported to express MRC1 
raising the possibility that some VEGFA-expressing MRC1+ cells in CTX-treated tumours might 
have been MDSCs (28).  However, we found that both granulocytic (CD45+CD11b+Ly6G+) and 
monocytic (CD45+CD11b+Ly6G-Ly6C+) MDSC subsets were depleted in CTX-treated tumours, 
and that the expression of MRC1 on monocytic MDSCs was significantly (P<0.05) lower than 
that on TAMs (Fig. S3C). Taken together, these data suggest that MDSCs are unlikely to 
represent a significant proportion of the MRC1Hi cells in our LLC1 tumors. 
 We previously showed that a subset of TAMs accumulate in hypoxic areas of untreated 
mouse and human tumors (29), where they respond to hypoxia by upregulating hypoxia-
11 
 
inducible factors (HIFs) 1 and 2 and a wide array of HIF-dependent M2 genes (30). As we 
detected some MRC1+ TAMs in the hypoxic regions of CTX-treated LLC1 tumors (Fig. S4A), 
albeit at much lower numbers than in the well-vascularised, normoxic (PIMO−) regions (Fig. 4A), 
we investigated the possibility that hypoxia-regulated transcriptional programming (via HIFs 1 
and 2) might contribute to the relapse-promoting functions of TAMs.  LLC1s were implanted into 
LysMCre/+HIF1fl/fl or LysMcre/+HIF2fl/fl myeloid-specific knockout mice and treated with vehicle or 
CTX.  HIF knockout was seen to have no effect on the number of MRC1+ TAMs in either the 
hypoxic or PIMO− areas in CTX-treated LLC1s, nor on tumor relapse (Fig. S4B&C). 
Immunohistochemical staining demonstrated a reduction of >90% in TAMs expressing HIF-1α 
or 2α in control LLC1s, confirming high efficiency of LysCre-targeted HIF allele ablation in our 
mice (Fig. S4D). These data suggest that hypoxia and HIF1/2-regulated transcriptional 
programming do not regulate the relapse-promoting functions of MRC1+ TAMs. 
 
MRC1+ TAMs accumulate in well-vascularised areas of tumors after chemotherapy in 
both mouse and human tumors and promote tumor relapse: role of VEGFA 
Previous studies have shown that MRC1+ TAMs can reside close to blood vessels in untreated 
mouse tumors (10). Furthermore, the aforementioned HIF knockout study demonstrated an 
increase in MRC1+ TAMs in PIMO− vascularised areas (PIMO− VA) in CTX-treated tumors (Fig. 
S4B).  We, therefore, conducted a more detailed immunofluorescence staining analysis of the 
distribution of these cells in control and CTX-treated LLC1s.  This showed that, while MRC1+ 
TAMs were evenly distributed between PIMO− VA and PIMO+ hypoxic areas in size-matched 
control tumors, there was a significant (P<0.05) increase in the number of F4/80+MRC1+TAMs 
in the former in CTX-treated LLC1s (Fig. 4A).  As CTX treatment also resulted in reduced tumor 
vascularity (Fig. S1A) we normalized MRC1+ TAM numbers to CD31+ area in PIMO− VA of 
control and CTX-treated LLC1s.  Interestingly, this showed that the increase in MRC1+ TAMs in 
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PIMO− VA is independent of changes in the vasculature (Fig. 4A, far right panel). Further 
immunofluorescent analysis of 4T1 and PyMT-MMTV tumors demonstrated a similar increase in 
the number of vessel-associated MRC1+ TAMs after treatment with PTX and DOX, respectively 
(Fig. 4B). Furthermore, because the majority of MRC1+ TAMs co-expressed VEGFA in both 
control and CTX-treated LLCs this meant that there was also a significant increase in VEGFA+ 
TAMs in perivascular areas (Fig. 4C upper panel).  Interestingly, there was also a significant 
(P<0.05) increase in the number of MRC1+VEGFA+ TAMs in direct contact with the abluminal 
surface of the tumor vasculature in CTX-treated tumors (Fig. 4C lower panel). However, the 
preferential accumulation of MRC1+VEGFA+ TAMs in the PIMO_VA regions of chemotherapy-
treated tumors was no longer present following relapse, suggesting that the accumulation of 
MRC1+ TAMs was an acute, transient response to therapy (Fig. S5A).  MRC1+ TAMs were also 
seen to preferentially localize in perivascular areas (ie. within 150µm of blood vessels) in human 
breast carcinomas 21-28 days after 3 cycles of neoadjuvant PTX (Fig. 4D left and middle 
panels), and in breast cancer metastases in the bone after chemotherapy (with or without 
bisphosphonates) (Fig. 4D right panel).  
 Immunofluorescence staining of VEGFA in orthotopic MMTV-PyMT tumors excised at 
day 6 indicated that only MRC1+, not MRC1−, TAMs expressed detectable levels of VEGFA in 
vehicle and DOX-injected Cre− tumors. Indeed, >98% of vessel-associated MRC1+ TAMs were 
VEGFA+ in both groups of tumors (Fig. 5A&B).  So, we investigated the role of VEGFA 
expression by these MRC1+ TAMs in tumor relapse using the Csf1r-Mer-Cre-Mer inducible cre-
recombinase/estrogen receptor fusion protein model for the tamoxifen-induced ablation of 
VEGFA selectively in monocytes/macrophages (23).   
 Female Csf1r-Mer-iCre-Mer FVB/n mice were orthotopically implanted with syngeneic 
MMTV-PyMT tumors and administered tamoxifen 24h after a single injection of either vehicle or 
DOX. In addition, tamoxifen was given continuously thereafter to ensure VEGFA knockout until 
mice were sacrificed at the end of the experiment (day 14), with the same treatment given to 
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control Cre-recombinase negative mice (Fig. 5C).  As the implanted PyMT cells in these tumors 
did not carry the Csf1r-driven Cre recombinase and expression of Csf1r is largely confined to 
TAMs in such tumors, the knockdown of VEGFA was restricted to the macrophage lineage, a 
significant source of VEGFA in the PyMT model (31) (as in CTX-treated LLC1s).  Tamoxifen-
induced ablation of this TAM-derived VEGFA (Fig. 5C) caused a significant (P<0.05) delay in 
the growth of vehicle-treated MMTV-PyMT tumors (Fig. 5D). Furthermore, relapse of DOX-
treated tumors lacking VEGFA+ TAMs (Cre+) was significantly (P<0.05) slower than that of 
DOX-treated tumors in VEGFA-expressing (Cre−) mice (Fig. 5E).  This was accompanied by a 
significant (P<0.05) decrease in vessel area in these tumors (Fig. 5F).  
 
Pharmacological blockade of CXCR4 prevents perivascular accumulation of MRC1+ 
VEGFA+ TAMs after chemotherapy and delays tumor relapse. 
 The majority of F4/80+MRC1+ TAMs expressed the CXCL12 receptor, CXCR4 in both 
control and CTX-treated LLC1s (Fig. 6A) and 98% of all CXCR4-expressing cells were TAMs in 
CTX-treated LLC1 tumors, compared to 78% in control LLCs (where other cell types were also 
CXCR4+) (Fig. 6B).  As reported previously (32,33), LLC1 cells do not express CXCR4 (Fig. 
6A-B).  Moreover, less than 1% of CD31+ blood vessels expressed CXCR4 in CTX-treated 
tumors (Fig. 6C).  MRC1Hi TAMs in both control and CTX-treated tumors expressed elevated 
levels of CXCR4 compared with the MRC1Lo TAMs (Figure 6D).  
These changes in CXCR4+ cells after CTX were accompanied by a marked increase in 
tumor levels of its ligand, CXCL12, on day 6 (Fig. 6D, far right). These CXCL12+ cells were 
CD31− (Fig. 6E, left panel) and most likely tumor cells and/or fibroblasts (34).  As a hypoxia-
inducible gene (35), it was not surprising to find CXCL12 more highly expressed in hypoxic than 
normoxic areas of control LLC1 tumors. However, after CTX, tumor levels of HIFs-1 and 2 were 
markedly reduced in all areas of tumors (Fig. S6A, i and ii) but CXCL12 was abundant in both 
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hypoxic and normoxic, vascularised areas (Fig. S6B).  This suggested CXCL12 upregulation by 
factors other than hypoxia in such tumors.   
CTX is known to induce oxidative stress (36), a cellular response known to regulate the 
expression of CXCL12 (37), so we investigated the expression of a well-defined marker for 
oxidative stress, hemeoxygenase-1 (HMOX-1) in control vs CTX-treated tumors. Interestingly, 
this was found to be upregulated in perivascular, PIMO−, CXCL12-rich areas of tumors after 
CTX treatment but not in control tumors (Fig. S6C, i and ii).  Both MRC1+ TAMs and MRC1− 
cells expressed HMOX-1 in these vascularised areas (Fig. S6C iii).   
We then investigated whether CXCL12 might recruit and/or retain CXCR4+MRC1+ TAMs 
in LLC1 tumors. First, we showed in an in vitro chemotaxis assay that CXCL12 is selectively 
chemotactic for MRC1+/Hi TAMs isolated from LLC1 tumors (Fig. 6E, right panel).  Then we 
administered CTX to LLC1-bearing mice alone or in combination with the CXCR4 antagonist, 
plerixafor (AMD3100) (Fig 7A). This was feasible as TAMs were the predominant cell type 
expressing CXCR4 after CTX (Fig. 6B).  CXCR4 blockade significantly inhibited CTX-induced 
accumulation of F4/80+ MRC1+ TAMs in the PIMO− VA (while the numbers in PIMO+ areas of 
LLC1 tumors were unchanged, as was F4/80+ MRC1− TAMs in either of these areas) and 
delayed tumor relapse (Figs. 7A&B and S5B).  At day 10 (when tumors had relapsed in the 
CTX alone group), a similar distribution of MRC1+ TAMs was seen compared to day 6 (the start 
of the relapse period) (Fig. 7B&C). In addition, tumors administered CTX+AMD3100 contained 
significantly (P<0.05) shorter CD31+ blood vessels, higher levels of hypoxia and fewer BrdU+ 
(proliferating) cells than tumors exposed to CTX with the vehicle for AMD3100 (PBS) (Fig. 7D & 
Fig. S5C).  
We then examined the effect of CXCR4 blockade on the distribution of MRC1+ TAMs 
across PIMO− VAs in CTX-treated tumors.  Interestingly, this was found to significantly (P<0.05) 
reduce the number of MRC1+ TAMs in direct contact with the abluminal surface of CD31+ blood 
vessels (standardised by CD31+ vessel area as this differed between CTX+PBS and CTX+ 
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AMD3100 groups), and increase them elsewhere in the PIMO− VAs (Figure 7E). These data 
suggest that CXCR4 regulates the direct association of alternatively activated TAMs with blood 
vessels in CTX-treated LLC1s. 
A recent study demonstrated a marked rebound in the growth of pulmonary metastases 
after treatment with an antibody to CCL2 (38). This was the result of increased mobilization of 
monocytes from the bone marrow after CCL2 inhibition, and increased blood vessel formation 
and cancer cell proliferation in the lungs. We, therefore, investigated the possibility of a similar 
rebound effect after CXCR4 inhibition using AMD3100 as this could disrupt the bone marrow 
niche. When we extended the length of the AMD3100 experiment, primary LLC1 tumors 
relapsed eventually, but not at an accelerated rate, and mice receiving CTX+AMD3100 showed 
increased survival compared to those in the CTX alone group (or controls). Importantly, there 
was also no rebound in pulmonary metastases (Fig. S8).  
 
 
Discussion  
Our studies show that M2-skewed TAMs (MRC1+TIE2+CXCR4HiVEGFA+) selectively 
accumulate in vascularized, well-oxygenated areas of LLC1 tumors after treatment with CTX.  A 
similar increase in such vessel-associated, M2-skewed TAMs was also seen in orthotopic 4T1 
and MMTV-PyMT implants after treatment with PTX and DOX, respectively, and in human 
breast carcinomas following neoadjuvant treatment with PTX.  This perivascular accumulation 
was found to be CXCR4-dependent, especially the increased, direct contact of this TAM subset 
with the abluminal surface of blood vessels in chemotherapy-treated tumors. When this was 
disrupted using a CXCR4 inhibitor, tumor revascularisation and regrowth after chemotherapy 
were markedly impaired.  We also show, using an inducible, macrophage-specific, gene 
knockdown model that VEGFA expressed by such MRC1+ TAMs mediates, in part, their ability 
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to promote tumor relapse after therapy. Consistent with this, genetic deletion of HIF signaling in 
TAMs in hypoxic tumor areas had no effect on this.  
 The mobilisation, and accumulation in tumors, of such BMDCs as myelomonocytic cells, 
MDSCs, endothelial progenitor cells (EPCs) and macrophages after various forms of anti-
cancer therapy is now well-established (13-19,39,40). However, our data show that M2-skewed 
TAMs represent a significant proportion of such BMDCs in tumors after chemotherapy, and is 
not accompanied by TAM proliferation or increased numbers of stem/progenitor cells. These 
data suggest that increased recruitment of circulating monocytes precedes the accumulation of 
such M2 TAMs in tumors after chemotherapy. It remains to be seen whether monocytes are 
already M2-skewed upon arrival in treated tumors and/or activated by factors produced in the 
perivascular niche.  Of note, the recruitment, activation and perivascular retention of these cells 
does not appear to be just an acute response to chemotherapy-induced tumor damage, as 
increased numbers of perivascular M2 TAMs persisted throughout the relapse phase.  
 Our observations suggest that the accumulation of MRC1+VEGFA+ TAMs on and around 
the tumor vasculature plays an important part in tumor revascularisation and relapse after 
chemotherapy. Furthermore, this was accompanied by a marked change in the pattern of 
CXCL12 expression in tumors.  While CXCL12 was mainly confined to hypoxic areas of control 
tumors, it was upregulated in vascularised, well oxygenated areas after chemotherapy. This 
correlated with an increase in the expression of the enzyme, HMOX-1, a marker of oxidative 
stress, in such perivascular areas.  Cytotoxic agents like CTX induce oxidative stress in tumors 
(41) which activates cellular expression of HMOX-1.  This, in turn, generates carbon monoxide 
from the breakdown of heme - a gas known to upregulate both CXCL12 and VEGFA in 
neighbouring cells (37). Interestingly, HMOX-1 also regulates expression of MRC1 by 
macrophages (42).  So, chemotherapy-induction of this stress pathway in perivascular areas 
could both retain TAMs via local CXCL12 induction, and upregulate their expression of VEGFA 
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and MRC1.  Interestingly, the CXCL12-induced retention of myeloid cells around the 
vasculature is also essential to the process of neovascularization in non-malignant tissues (43).  
 Other factors may also contribute to the retention of MRC1+ TAMs. Our observation that 
MRC1+ TAMs expressed elevated TIE2 suggests that ANGPT2 expressed by the tumor 
endothelium (44) might also be involved. Indeed, ANGPT2 has an established role in retaining 
vascular modulatory myeloid cells in proximity to the vasculature in progressing mouse tumors 
(26).   
In untreated mouse tumors, perivascular, M2-skewed TAMs have an established 
vascular modulatory role and facilitate tumor growth and progression (26).  Our observation that 
chemotherapy induces the accumulation of MRC1+VEGFA+ TAMs around tumor blood vessels 
strongly infers a proangiogenic role for these cells. This is supported by our finding that 
pharmacological inhibition of their chemotherapy-induced accumulation resulted in reduced 
subsequent tumor revascularisation. Furthermore, in DOX-treated, MMTV-PyMT tumor implants 
VEGFA was found to be expressed predominantly by MRC1+ TAMs, consistent with our 
previous finding that TAMs are a major source of VEGFA in MMTV-PyMT tumors (31). The 
selective ablation of VEGFA in MRC1+ TAMs resulted in delayed tumor relapse, post-therapy.  
However, PyMT tumors still relapsed, albeit at a reduced rate, in the absence of TAM-derived 
VEGFA, indicating that other TAM-derived factors may also contribute to tumor relapse and/or 
the possible induction of resistance mechanisms in tumors to VEGFA knockout. The presence 
of the latter has been demonstrated in tumors after anti-VEGFA therapy and shown to include 
increased expression of such alternative pro-angiogenic mediators as FGF2 (45), ANGPT2 (46) 
or PlGF (47) and the recruitment of tumor-promoting, CD11b+ Gr1+ myeloid cells (48). 
Recently, the Condeelis group have used intravital imaging to characterise a distinct 
subset of perivascular TAMs in untreated mouse tumors that make contact with endothelial cells 
and tumor cells expressing high levels of Mena (a protein that enhances their motility), and 
directly stimulate tumor cell intravasation (49).  These cell trios have been termed ‘Tumor 
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Microenvironments of Metastasis’ (TMEMs).  It is possible that some of the perivascular MRC1+ 
M2-skewed TAMs accumulating around tumor blood vessels after chemotherapy form TMEMs 
and promote metastasis as well as relapse – a dangerous combination in patients with 
inoperable tumors.   
The effect of CXCR4 blockade on tumor relapse after chemotherapy in our study 
suggests that CXCR4 inhibitors might be successfully combined with chemotherapy.  This 
combination could extend relapse-free survival in patients with inoperable tumors, although our 
data suggests that multiple rounds of the inhibitor would have to be administered to maintain a 
suppressive effect on relapse.  Such sustained use of a CXCR4 antagonist after chemotherapy 
could conceivably disrupt the marrow niche.  However, this is unlikely to lead to clinical 
problems as a recent, first-in-human clinical trial has shown that repeated daily injections of the 
CXCR4 antagonist, LY2510924 over a number of consecutive, 28-day cycles was well tolerated 
in advanced cancer patients (50).  
Taken together, our data suggest that the selective targeting of relapse-promoting, 
perivascular TAMs could delay the relapse of both primary and metastatic tumors in patients 
after chemotherapy, thereby extending their relapse-free survival. 
 
Acknowledgments 
This study was supported mainly by a Cancer Research UK grant to CEL. She also gratefully 
acknowledges the support of Yorkshire Cancer Research. Other authors acknowledge the grant 
support of the Swiss Cancer League (to MDP), Breast Cancer Research Foundation (to OCO & 
JAJ), a Chancellor’s Fellowship from the University of Edinburgh (to B-ZQ), and The Wellcome 
Trust (Senior Investigator Award) to JWP. 
 
 
 
19 
 
References 
1. Savir G, Huber KE, Saif MW. Locally advanced pancreatic cancer. Looking beyond 
traditional chemotherapy and radiation. JOP : Journal of the pancreas 2013;14(4):337-9. 
2. Strom HH, Bremnes RM, Sundstrom SH, Helbekkmo N, Aasebo U. Poor prognosis 
patients with inoperable locally advanced NSCLC and large tumors benefit from 
palliative chemoradiotherapy: a subset analysis from a randomized clinical phase III trial. 
Journal of thoracic oncology : official publication of the International Association for the 
Study of Lung Cancer 2014;9(6):825-33. 
3. Coffelt SB, Lewis CE, Naldini L, Brown JM, Ferrara N, De Palma M. Elusive identities 
and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol 
2010;176(4):1564-76. 
4. Noy R, Pollard JW. Tumor-Associated Macrophages: From Mechanisms to Therapy. 
Immunity 2014;41(1):49-61. 
5. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and 
metastasis. Cell 2010;141(1):39-51. 
6. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, et al. 
Different tumor microenvironments contain functionally distinct subsets of macrophages 
derived from Ly6C(high) monocytes. Cancer Res 2010;70(14):5728-39. 
7. Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of 
angiogenesis and tumor progression. Biochimica et biophysica acta 2009;1796(1):11-8. 
8. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor 
progression: regulation by distinct molecular mechanisms. Journal of immunology 
2008;180(4):2011-7. 
9. Pucci F, Venneri MA, Biziato D, Nonis A, Moi D, Sica A, et al. A distinguishing gene 
signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" 
20 
 
monocytes, and embryonic macrophages suggests common functions and 
developmental relationships. Blood 2009;114(4):901-14. 
10. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, et al. Tie2 
identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel 
formation and a mesenchymal population of pericyte progenitors. Cancer Cell 
2005;8(3):211-26. 
11. Daenen LG, Houthuijzen JM, Cirkel GA, Roodhart JM, Shaked Y, Voest EE. Treatment-
induced host-mediated mechanisms reducing the efficacy of antitumor therapies. 
Oncogene 2014;33(11):1341-7. 
12. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer 
therapies. Cancer Cell 2013;23(3):277-86. 
13. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. 
Leukocyte complexity predicts breast cancer survival and functionally regulates 
response to chemotherapy. Cancer Discov 2011;1(1):54-67. 
14. Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ, et al. Imaging tumor-
stroma interactions during chemotherapy reveals contributions of the microenvironment 
to resistance. Cancer Cell 2012;21(4):488-503. 
15. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, et al. Macrophages and 
cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 
2011;25(23):2465-79. 
16. Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM. Inhibition of Mac-1 
(CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell 
recruitment. Proc Natl Acad Sci U S A 2010;107(18):8363-8. 
17. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of 
vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after 
irradiation in mice. J Clin Invest 2010;120(3):694-705. 
21 
 
18. Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of 
myeloid but not endothelial precursor cells facilitates tumor regrowth after local 
irradiation. Cancer Res 2010;70(14):5679-85. 
19. Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, et al. TIE2-expressing 
macrophages limit the therapeutic efficacy of the vascular-disrupting agent 
combretastatin A4 phosphate in mice. J Clin Invest 2011;121(5):1969-73. 
20. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and 
polarization in tissue repair and remodelling. The Journal of pathology 2013;229(2):176-
85. 
21. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. 
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental 
drug-resistant cancer. Cancer Res 2000;60(7):1878-86. 
22. Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, et al. B cells 
regulate macrophage phenotype and response to chemotherapy in squamous 
carcinomas. Cancer Cell 2014;25(6):809-21. 
23. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits 
inflammatory monocytes to facilitate breast-tumour metastasis. Nature 
2011;475(7355):222-5. 
24. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, et al. Direct visualization of 
macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 
2007;67(6):2649-56. 
25. Hilton JF, Amir E, Hopkins S, Nabavi M, DiPrimio G, Sheikh A, et al. Acquisition of 
metastatic tissue from patients with bone metastases from breast cancer. Breast cancer 
research and treatment 2011;129(3):761-5. 
22 
 
26. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, et al. Targeting the 
ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and 
disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011;19(4):512-26. 
27. Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, et al. 
Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. 
Nature 2008;456(7223):814-8. 
28. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel 
chemoimmunomodulating property of docetaxel: suppression of myeloid-derived 
suppressor cells in tumor bearers. Clin Cancer Res 2010;16(18):4583-94. 
29. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of 
macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 
2004;104(8):2224-34. 
30. Fang HY, Hughes R, Murdoch C, Coffelt SB, Biswas SK, Harris AL, et al. Hypoxia-
inducible factors 1 and 2 are important transcriptional effectors in primary macrophages 
experiencing hypoxia. Blood 2009;114(4):844-59. 
31. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages regulate the 
angiogenic switch in a mouse model of breast cancer. Cancer Res 2006;66(23):11238-
46. 
32. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, et al. 
CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on 
tumor-associated vasculature. Proc Natl Acad Sci U S A 2007;104(40):15735-40. 
33. Weiss ID, Jacobson O, Kiesewetter DO, Jacobus JP, Szajek LP, Chen X, et al. Positron 
emission tomography imaging of tumors expressing the human chemokine receptor 
CXCR4 in mice with the use of 64Cu-AMD3100. Molecular imaging and biology : MIB : 
the official publication of the Academy of Molecular Imaging 2012;14(1):106-14. 
23 
 
34. Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, et al. Targeting 
CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-
PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 
2013;110(50):20212-7. 
35. Hitchon C, Wong K, Ma G, Reed J, Lyttle D, El-Gabalawy H. Hypoxia-induced 
production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth 
factor by synovial fibroblasts. Arthritis and rheumatism 2002;46(10):2587-97. 
36. Li L, Jiang L, Geng C, Cao J, Zhong L. The role of oxidative stress in acrolein-induced 
DNA damage in HepG2 cells. Free radical research 2008;42(4):354-61. 
37. Lin HH, Chen YH, Chang PF, Lee YT, Yet SF, Chau LY. Heme oxygenase-1 promotes 
neovascularization in ischemic heart by coinduction of VEGF and SDF-1. Journal of 
molecular and cellular cardiology 2008;45(1):44-55. 
38. Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, et al. Cessation of 
CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. 
Nature 2014;515(7525):130-3. 
39. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. 
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer 
stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. 
Cancer Immunol Immunother 2009;58(1):49-59. 
40. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, et al. Rapid 
chemotherapy-induced acute endothelial progenitor cell mobilization: implications for 
antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14(3):263-73. 
41. Chen Y, Jungsuwadee P, Vore M, Butterfield DA, St Clair DK. Collateral damage in 
cancer chemotherapy: oxidative stress in nontargeted tissues. Molecular interventions 
2007;7(3):147-56. 
24 
 
42. Tu TH, Joe Y, Choi HS, Chung HT, Yu R. Induction of heme oxygenase-1 with hemin 
reduces obesity-induced adipose tissue inflammation via adipose macrophage 
phenotype switching. Mediators of inflammation 2014;2014:290708. 
43. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, et al. VEGF-induced 
adult neovascularization: recruitment, retention, and role of accessory cells. Cell 
2006;124(1):175-89. 
44. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and 
angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 
1998;153(5):1459-66. 
45. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of 
antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer 
Cell 2005;8(4):299-309. 
46. Rigamonti N KE, Keklikoglou I, Rmili CW, Leow CC, De Palma M. Role of angiopoietin-2 
in adaptive tumor resistance to VEGF signalling blockade. Cell Reports 2014;Cell 
Reports (July 31, 2014). 
47. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, et al. Anti-PlGF 
inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. 
Cell 2007;131(3):463-75. 
48. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, et al. Tumor refractoriness 
to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 
2007;25(8):911-20. 
49. Roussos ET, Goswami S, Balsamo M, Wang Y, Stobezki R, Adler E, et al. Mena 
invasive (Mena(INV)) and Mena11a isoforms play distinct roles in breast cancer cell 
cohesion and association with TMEM. Clinical & experimental metastasis 
2011;28(6):515-27. 
25 
 
50. Galsky MD, Vogelzang NJ, Conkling P, Raddad E, Polzer J, Roberson S, et al. A Phase 
I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer. 
Clin Cancer Res 2014;20(13):3581-8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
26 
 
Figure Legends 
Figure 1. Effects of cyclophosphamide (CTX) on tumor growth and accumulation of M2 
TAMs in LLC1 tumors. (A) Growth kinetics of LLC1s following three i.p. injections with either 
150 mg/kg CTX or PBS (left), the number of MRC1+ or MRC1− F4/80+ TAMs (right) (n=7-
8/group), and (B) their cell-surface expression of MRC1, as detected by flow cytometry (n=5-
6/group), two days after the last dose of CTX (day 6, ie prior to the regrowth phase). (C) Flow 
cytometric analysis of TIE2 and MRC1 on TAMs from CTX-treated tumors. (D) Co-localization of 
MRC1 and TIE2 on TAMs in CTX-treated tumors (see yellow arrows and inset for dual-stained 
cells). V = vessel. Bars=50 µm.  *P<0.05. 
 
Figure 2. Effects of adoptive transfer of MRC1Hi vs MRC1Lo TAMs on LLC1 relapse after 
CTX. (A) Design schematic of the TAM transfer experiment. (B) Quantification of MRC1+ TAMs 
in tumors receiving adoptive transfer of MRC1-/Lo or MRC1+/Hi TAMs. (C) LLC1 regrowth after the 
last CTX injection (‘day 0’). (D) Vascularisation and (E) proliferation in LLC1 tumors receiving 
MRC1Hi or MRC1Lo (n = 5/group). Co-staining of CTX-treated LLC1 tumor sections with 
antibodies against the pan-leukocyte marker (CD45) and BrdU.  Fewer than 1% of proliferating 
cells were leukocytes in either group.  *P<0.05. Bars=50 µm. 
 
Figure 3. Effect of CTX on the number of MRC1+ VEGFA+ TAMs in LLC1 tumors and 
VEGFA release by TAMs in vitro. (A) Representative immunostaining for F4/80+, MRC1+ and 
VEGFA+. VEGF-expressing F4/80− cells (yellow arrows) and F4/80+ TAMs (orange arrows). (B) 
VEGFA co-localization with MRC1 in TAMs. Bar=50 µm. (C) Number of MRC1+ VEGFA+ TAMs. 
(D) VEGFA release by CD45+CD11b+Ly6G-F4/80+ TAMs (VEGFA release in medium over 16h, 
standardised by live TAM numbers) *P<0.05. 
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Figure 4. Effect of cytotoxic drugs on the distribution of MRC1+ TAMs in mouse and 
human tumors: co-localization with VEGFA.  (A) Immunostaining of MRC1+ TAMs in 
PIMO−VA and hypoxic (PIMO+) areas of LLC1 tumors, 48h after last injection of CTX (left and 
middle), and their abundance in PIMO− VA areas normalised by CD31+ area (right) (n=4/group). 
(B) MRC1+ TAM accumulation in vessel-associated (‘VA’) areas in 4T1 (n=8-9/group) and 
MMTV-PyMT tumor implants after treatment with PTX or DOX respectively (n=7/group). (C) 
Overall number of MRC1+VEGFA+ TAMs in PIMO− VA (upper) and the number in direct contact 
with CD31+ vessels (‘abluminal’; lower panel) in control and CTX-treated LLCs 48h after the 
final dose of CTX (both normalized by total CD31+ area). (D) MRC1+ TAMs in vascular or 
avascular areas of human primary carcinomas three weeks after three cycles of PTX treatment 
(black arrows; n=4 biopsies). MRC1+ macrophages near vessels in bone metastases from 
patients with advanced breast cancer following treatment (red arrows; n=4 biopsies). 
Bars=50µm. *P<0.05. 
 
Figure 5. Effect of TAM-derived VEGFA on relapse of orthotopic MMTV-PyMT tumors 
after DOX treatment. (A) Representative immunostaining for VEGFA in MRC1+ TAMs in 
vascularised (CD31+) areas of DOX-treated, Cre−, MMTV-PyMT tumors. This was not seen for 
MRC1− TAMs anywhere in the same tumors (B). (C) Female Tg(Csf1r-Mer-iCre-
Mer)1jwp;Vegfafl/fl) mice bearing MMTV-PyMT tumors were administered tamoxifen for 24h to 
delete VEGFA expression in TAMs (pictures, right) after a single injection of either vehicle alone 
or DOX. (D) Growth of tumors treated with vehicle alone in Cre+ and Cre− mice (n=3-6/group) 
and (E) regrowth of tumors in Cre+ and Cre− mice after treatment with DOX (n=3-4/group). (F) 
CD31 staining of vessels in tumors in Cre− or Cre+ mice given Dox.  Bars=50µm. *P<0.05 w.r.t. 
tumors at the same time point in the respective Cre− group. + P<0.05. 
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Figure 6. Expression of CXCR4 by MRC1+ TAMs and upregulation of CXCLl2 in LLC1 
tumors following CTX treatment. (A) Immunostaining of F4/80 and CXCR4, and (B) the % of 
CXCR4+ cells co-expressing F4/80 in control and CTX-treated LLCs (n=4/group). (C) 
Immunostaining of CXCR4 and CD31 in CTX-treated LLCs. (D) Flow cytometric analysis of 
TAM expression of CXCR4 and MRC1 in dispersed CTX-treated LLCs  (left panel), CXCR4 MFI 
on MRC1+ vs. MRC1- TAMs (middle panel) (n=4-5/group), and tumor levels of 
immunodetectable CXCL12 protein in control and CTX-treated tumors (n=4/group) (right panel). 
(E) CXCL12+ cells were perivascular in CTX-treated LLC1s (left panel) and exogenous rec 
human CXCL12 was chemotactic for MRC1+/Hi (but not MRC-/Lo) TAMs isolated from LLC1 
tumors.  Bars=50 µm. *P<0.05. 
 
Figure 7. Effect of the CXCR4 inhibitor, AMD3100 on LLC1 relapse after CTX: role of 
perivascular MRC1+CXCR4Hi TAMs. (A) Regrowth of tumors in mice treated with PBS, 
PBS+AMD3100, CTX+PBS, or CTX+AMD3100 (n=5-9/group). (B) F4/80+MRC1+ TAMs in the 
PIMO− VA and hypoxic (PIMO+) areas of CTX+PBS or CTX+AMD3100 treated tumors (n=4-
6/group) at days 6 and (C) day 10 (n=7-9/group). (D) Total CD31+ vessel area in tumors treated 
with CTX+PBS and CTX+AMD3100 (at day 6 in panel A). (E) MRC1+ TAMs in direct contact 
(‘abluminal) or not in contact with (‘non-abluminal’) with CD31+ endothelial cells in PIMO- VA 
areas of either CTX+PBS or CTX+AMD3100 treated LLCs (normalised to total CD31+ area in 
each FOV). *P<0.05.   
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Figure S1. Effects of various cytotoxic agents on TAM accumulation in three 
mouse tumor models.  (A)  CD31+ vessel length and the % of tumor areas that 
were PIMO+ in control and CTX-treated LLC1 tumors 48 h after the last injection of 
CTX (day 6) (n = 6-12/group). (B) Gating strategy for flow cytometric analysis of the 
proportion of CD45+ CD11b+ Ly6G- F4/80+ TAMs (expressed as a % of viable CD45+ 
leukocytes). Dispersed LLC1s were gated on viable cells (1) followed by the pan-
leukocyte marker CD45 (2). Neutrophils were identified and excluded from further 
analyses by gating on CD11b+ Ly6G- cells (3). Finally, mature macrophages were 
identified on the basis of Ly6CHI F4/80Hi marker profile (n = 5-6/group). (C) 
Immunofluorescent quantification of F4/80+ TAMs in control and CTX-treated LLCs (n 
= 7-8/group), control and PTX-treated orthotopic 4T1s (n= 8-9/group), and control 
and DOX-treated orthotopic MMTV-PyMT tumors (n = 7/group). (D) F4/80+ MRC1+ 
TAM numbers in CD31+ vessel-associated areas in control and PTX-treated 
orthotopic 4T1 tumors (n = 8-9/group) or control and DOX-treated orthotopic MMTV-
PyMT tumors (n = 8-9/group). The 'Control' group in each case is the vehicle for the 
cytotoxic agent. *P<0.05. 
 
Figure S2. Further Characterization of MRC1+ TAMs in mouse tumors. (A) Co-
localization of MRC1 with F4/80 in LLC1 (n = 4-6/group), 4T1 (n = 5-6/group) and 
MMTV-PyMT tumors (n = 4/group). (B) Immunofluorescent labelling of BrdU and 
MRC1 (n = 4/group) or the (C) HSC markers, c-kit or Sca-1 (although occasional, 
single Sca-1+ cells were evident) in tumors 48 h after the last injection of CTX. 
*P<0.05.  Bars = 50 µm.   
 
Figure S3. VEGFA lmmunofluorescence in control and CTX-treated LLC1 
tumors.  (A) Representative immunostaining of VEGFA and MRC1+ TAMs in 
vascularised, PIMO- VA and PIMO+ (hypoxic) areas of control and CTX-treated 
tumors. (B) The proportion VEGF-expressing cells that were either MRC1− cells (ie. 
non-TAMs) (left) or MRC1+ TAMs (right) in the above areas. (C) These MRC1+ cells 
were not MDSCs as immature, ‘monocytic MDSCs’ (CD45+CD11b+Ly6G-Ly6C+ cells) 
and granulocytic MDSCs (CD45+CD11b+Ly6G+ cells) were depleted in CTX-treated 
tumours.  Also immature, ‘monocytic MDSCs’ from these tumors expressed very low 
levels of MRC1 (lower panels).  *P<0.05.   
 
Figure S4. Role of hypoxic (ie. HIF-expressing) TAMs in relapse of LLC1 
tumors after CTX. (A) Immunofluorescence staining of MRC1+ TAMs in PIMO+ 
(hypoxic) areas of tumors 48h after CTX treatment (ie. prior to the start of 
tumor regrowth). Bar=50 µm. (B) Quantification of MRC1+ TAM numbers in the 
PIMO+ and PIMO- areas of WT, HIF1KO and HIF2KO tumors (n = 5/group). (C) Growth 
of tumors of WT, HIF1KO (left) and HIF2KO (right) mice showing the initial response of 
to CTX administration (3 black arrows), or their subsequent relapse (n = 3-5 
mice/group at endpoint). (D) lmmunohistochemical labelling of HIF-1α and HIF-2α in 
TAMs in vehicle-treated tumors confirmed the Lys-Cre deletion of these genes in 
HIF-1 and 2α ko mice. 
 
Figure S5. Effect of CXCR4 blockade on various tumor parameters in CTX-
treated LLC1 tumors. (A) The number of MRC1+ TAMs in PIMO_VA vs. hypoxic 
regions and representative images of VEGF expression by MRC1+ TAMs in 
PIMO_VA regions of CTX-treated tumours 48hr after the last dose and following 
relapse. (B) The number of MRC1- TAMs in well-vascularised PIMO− VA and 
hypoxic, PIMO+ areas of tumors given CTX in combination with saline or AMD3100 
was quantified by immunofluorescence staining at 6 days post-therapy. (C) 
Quantification of CD31+ vessels length, the % PIMO+ tumor area and the numbers of 
BrdU+ proliferating cells in tumors from mice, 6 days after administration of either 
CTX + vehicle (PBS) or CTX + AMD3100. *P<0.05. 
 Figure S6. Co-localization of HIFs 1 and 2, but not CXCL12 or HO-1, with 
hypoxia in LLC1s. (A) Representative staining of: (i) HIF-1α in paraffin-wax sections 
or (ii) HIF-2α in frozen sections of LLC1 tumors (top panels). HIF-1α expression was 
widespread in PBS-treated control tumors whereas HIF-2α was upregulated in 
hypoxic areas.  Both α subunits were reduced after CTX. (B) CXCL12 is found 
mainly in hypoxic areas of control LLC1s, but expressed in both normoxic and 
hypoxic tumor areas after CTX. (C) The oxidative stress marker, HMOX-1, was 
upregulated in PIMO− CXCL12-rich perivascular areas of CTX-treated tumours (i & ii) 
where it was expressed by both MRC1+ and MRC1− cells (white or yellow arrows 
respectively) (iii). Bars=50µm *P<0.05. 
 
Figure S7. Effect of CXCR4 blockade on the longer-term re-growth kinetics of 
primary and metastatic LLC1s. Extending the relapse period of mice treated with 
PBS, AMD3100, CTX or CTX+ AMD3100 showed that neither primary tumors (A) nor 
their pulmonary metastases (B) had accelerated regrowth (ie. rebounded) after 
cessation of the AMD3100 treatment. 
 
 







